These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 15939196

  • 1. Gastrointestinal stromal tumors.
    von Mehren M, Watson JC.
    Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P.
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [Abstract] [Full Text] [Related]

  • 3. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K, Matsumoto T, Hirota S.
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE, Blanke CD.
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [Abstract] [Full Text] [Related]

  • 5. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S.
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [Abstract] [Full Text] [Related]

  • 6. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y, Hou YY, Tan YS, Lu SH, Hou J, Liu JL, Qin J, Shen KT, Sun YH.
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [Abstract] [Full Text] [Related]

  • 7. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Aug; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 8. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
    Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF.
    J Surg Oncol; 2010 Nov 01; 102(6):599-603. PubMed ID: 20976730
    [Abstract] [Full Text] [Related]

  • 9. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T.
    Gan To Kagaku Ryoho; 2004 Oct 01; 31(11):1791-4. PubMed ID: 15553717
    [Abstract] [Full Text] [Related]

  • 10. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ, Wilson L, Blanke CD.
    Clin Cancer Res; 2009 Jun 15; 15(12):3908-11. PubMed ID: 19509180
    [Abstract] [Full Text] [Related]

  • 11. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S.
    Clin Cancer Res; 2007 Apr 15; 13(8):2369-77. PubMed ID: 17438095
    [Abstract] [Full Text] [Related]

  • 12. Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
    Sleijfer S, Wiemer E, Verweij J.
    Nat Clin Pract Oncol; 2008 Feb 15; 5(2):102-11. PubMed ID: 18235442
    [Abstract] [Full Text] [Related]

  • 13. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
    Samelis GF, Ekmektzoglou KA, Zografos GC.
    Eur J Surg Oncol; 2007 Oct 15; 33(8):942-50. PubMed ID: 17196360
    [Abstract] [Full Text] [Related]

  • 14. Pathology of gastrointestinal stromal tumors.
    Hirota S, Isozaki K.
    Pathol Int; 2006 Jan 15; 56(1):1-9. PubMed ID: 16398673
    [Abstract] [Full Text] [Related]

  • 15. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    Oncology; 2009 Jan 15; 76(5):326-32. PubMed ID: 19307738
    [Abstract] [Full Text] [Related]

  • 16. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM.
    Histopathology; 2006 Jul 15; 49(1):52-65. PubMed ID: 16842246
    [Abstract] [Full Text] [Related]

  • 17. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
    Kosmadakis N, Visvardis EE, Kartsaklis P, Tsimara M, Chatziantoniou A, Panopoulos I, Erato P, Capsambelis P.
    Surg Oncol; 2005 Aug 15; 14(2):75-84. PubMed ID: 15993051
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
    Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P, Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY.
    Expert Opin Pharmacother; 2008 May 15; 9(7):1211-22. PubMed ID: 18422477
    [Abstract] [Full Text] [Related]

  • 19. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
    Shen KT, Hou YY, Qin XY, Song LJ, Sujie A.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar 15; 8(2):129-31. PubMed ID: 16155822
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.